Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 132.87 USD -0.24% Market Closed
Market Cap: 19.5B USD

Gross Margin
Biogen Inc

75.6%
Current
77%
Average
63%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.6%
=
Gross Profit
7.4B
/
Revenue
9.8B

Gross Margin Across Competitors

Biogen Inc
Glance View

Economic Moat
None
Market Cap
19.5B USD
Industry
Biotechnology

Biogen Inc. finds its roots in the cutting-edge world of biotechnology, where science meets the needs of patients battling complex neurological diseases. Founded in 1978 by a group of visionary scientists, including Nobel laureates, Biogen has evolved into a leader known primarily for its focus on neuroscience. Nestled in Cambridge, Massachusetts, the company operates with a singular goal—transforming the understanding and treatment of neurological disorders. The enterprise drives its mission through rigorous research and development (R&D), which forms the backbone of its operations. Biogen invests substantial resources in unveiling the mysteries of diseases such as multiple sclerosis (MS), Alzheimer's, and spinal muscular atrophy, striving to pioneer therapies that can profoundly improve patient outcomes. Biogen's revenue model is heavily contingent upon the successful commercialization of its R&D endeavors. The company primarily earns its revenue by developing and marketing prescription drugs that target neurological conditions. Signature products, such as Tecfidera, Tysabri, and Spinraza, have become mainstays in the management of multiple sclerosis and spinal muscular atrophy, respectively, delivering significant returns. By continually reinvesting in its drug pipeline, Biogen stays at the forefront of biopharmaceutical innovation, seeking to expand its portfolio and rigging favorable licensing deals and collaborations along the way. These elements ensure not just the sustenance but also the growth of its market presence, driving the company forward in a competitive and ever-evolving industry landscape.

BIIB Intrinsic Value
173.07 USD
Undervaluation 23%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
75.6%
=
Gross Profit
7.4B
/
Revenue
9.8B
What is the Gross Margin of Biogen Inc?

Based on Biogen Inc's most recent financial statements, the company has Gross Margin of 75.6%.

Back to Top